301166.Sz

The company maintains a strong liquidity position, with a current ratio of 8.7, indicating a high ability to meet short-term obligations. However, its free cash flow is negative at -79,358,890 CNY, which may signal reinvestment in operations or capital expenditures. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing.

Profitability metrics show a return on equity of 0.49% and a return on assets of 0.44%, both of which are below the typical thresholds for pharmaceutical firms, indicating suboptimal returns relative to industry expectations. The operating income of 733,000 CNY and net income of 10,149,050 CNY suggest limited profitability, which may be a concern for investors.

The company's revenue is concentrated in a single entity, with no disclosed geographic or segment diversification, which could expose it to regional or product-specific risks. This lack of diversification may limit its ability to adapt to market changes or regulatory shifts.

The company's growth trajectory is not clearly defined, as there are no specific numeric deltas provided for the current or next fiscal year. The negative free cash flow and limited operating income suggest that the company may be reinvesting heavily in its operations or facing operational challenges.

The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could affect its ability to fund operations without external financing. There are no specific dilution sources identified, and the dilution potential is considered low.

Recent events and filings do not provide specific details on the company's strategic direction or operational changes. The absence of detailed disclosures may limit the ability to assess the company's future performance accurately.